The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A member of the class of pyridopyrimidines that is pyrido[2,3-d]pyrimidine substituted by an amino group at position 2, 3,5-dimethoxyphenyl group at position 6, and by a (tert-butylcarbamoyl)nitrilo group at position 7. It is a selective ATP competitive inhibitor of the human fibroblast growth factor-1 receptor (FGFR1) tyrosine kinase with an IC50 of 52.4 nM.
PD 166866 inhibits the reaction [FGF1 protein results in increased abundance of Nitric Oxide]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of and results in increased secretion of NGF protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of NOS2 mRNA]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA]
PD 166866 results in decreased activity of FGFR1 protein PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]
PD 173074 results in decreased activity of FGFR1 protein PD 173074 results in decreased expression of FGFR1 protein [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [arsenic trioxide results in decreased expression of FGFR1 protein]
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] PD 173074 results in decreased activity of FGFR4 protein
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]
PD 173074 results in decreased phosphorylation of MAPK1 protein PD 173074 results in decreased expression of MAPK1 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]
PD 173074 results in decreased phosphorylation of MAPK3 protein PD 173074 results in decreased expression of MAPK3 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]
[arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]
PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of RAF1 protein modified form; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]
[arsenic trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [arsenic trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [arsenic trioxide results in decreased expression of SRC protein] PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form
PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein]
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]
browse the term
